91 related articles for article (PubMed ID: 1333524)
1. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours.
Soini Y; Vähäkangas K; Nuorva K; Kamel D; Lane DP; Pääkkö P
J Pathol; 1992 Sep; 168(1):29-33. PubMed ID: 1333524
[TBL] [Abstract][Full Text] [Related]
2. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53.
Oshiro Y; Fukuda T; Tsuneyoshi M
Am J Surg Pathol; 1994 Jul; 18(7):712-9. PubMed ID: 7517104
[TBL] [Abstract][Full Text] [Related]
3. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
5. Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis.
Osaki M; Osaki M; Yamashita H; Shomori K; Yoshida H; Ito H
Int J Mol Med; 2002 Aug; 10(2):161-8. PubMed ID: 12119552
[TBL] [Abstract][Full Text] [Related]
6. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
[TBL] [Abstract][Full Text] [Related]
7. p53 abnormalities in different subtypes of human sarcomas.
Andreassen A; Oyjord T; Hovig E; Holm R; Flørenes VA; Nesland JM; Myklebost O; Høie J; Bruland OS; Børresen AL
Cancer Res; 1993 Feb; 53(3):468-71. PubMed ID: 8425179
[TBL] [Abstract][Full Text] [Related]
8. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
9. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues.
Fanburg-Smith JC; Miettinen M
Hum Pathol; 2001 Sep; 32(9):976-83. PubMed ID: 11567228
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA
Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456
[TBL] [Abstract][Full Text] [Related]
11. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
12. p53 immunostaining in the differentiation of inflammatory pseudotumor from sarcoma involving the lung.
Ledet SC; Brown RW; Cagle PT
Mod Pathol; 1995 Apr; 8(3):282-6. PubMed ID: 7617655
[TBL] [Abstract][Full Text] [Related]
13. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas.
Taubert H; Würl P; Meye A; Berger D; Thamm B; Neumann K; Hinze R; Schmidt H; Rath FW
Cancer; 1995 Oct; 76(7):1187-96. PubMed ID: 8630896
[TBL] [Abstract][Full Text] [Related]
14. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings.
Eeles RA; Warren W; Knee G; Bartek J; Averill D; Stratton MR; Blake PR; Tait DM; Lane DP; Easton DF
Oncogene; 1993 May; 8(5):1269-76. PubMed ID: 8479749
[TBL] [Abstract][Full Text] [Related]
15. bcl-2 is preferentially expressed in tumours of muscle origin but is not related to p53 expression.
Soini Y; Pääkkö P
Histopathology; 1996 Feb; 28(2):141-5. PubMed ID: 8834522
[TBL] [Abstract][Full Text] [Related]
16. [Detection of point mutation of p53 gene by silver staining PCR-SSCP in paraffin-embedded malignant fibrous histiocytoma].
Li J; Yang G; Li G
Zhonghua Zhong Liu Za Zhi; 1996 Jan; 18(1):13-5. PubMed ID: 8732103
[TBL] [Abstract][Full Text] [Related]
17. Malignant fibrous histiocytoma phenotype in pleomorphic sarcoma differentiation in recurrent disease.
Costa MJ
Arch Pathol Lab Med; 1994 Feb; 118(2):160-4. PubMed ID: 8311656
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling.
Lee YF; John M; Edwards S; Clark J; Flohr P; Maillard K; Edema M; Baker L; Mangham DC; Grimer R; Wooster R; Thomas JM; Fisher C; Judson I; Cooper CS
Br J Cancer; 2003 Feb; 88(4):510-5. PubMed ID: 12592363
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature.
Carlson JW; Fletcher CD
Histopathology; 2007 Oct; 51(4):509-14. PubMed ID: 17711447
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity for laminin and type IV collagen in malignant and benign fibrous histiocytoma.
Soini Y; Autio-Harmainen H; Miettinen M
J Pathol; 1989 Jul; 158(3):223-8. PubMed ID: 2549228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
